RGLS Regulus: Net earnings per share for the last four quarters
The reliability of Regulus Therapeutics (RGLS) is based on the development of targeted oligonucleotides for the therapy of rare renal pathologies. Annual EPS growth according to financial statements (TTM) confirms the market dynamics, where the value is recorded at 25.40. The innovative miRNA ecosystem allows for the mitigation of the root causes of diseases, while the success of phase one trials and patent protection create a solid foundation for long-term business scaling.
Regulus Therapeutics Inc - analytical breakdowns and key metrics (RGLS)
- current quotes and average value forecast:
- company stock capitalization data:
- book value of equity indicators:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Regulus Therapeutics|RGLS - Long-Term Debt to Capital|Current Liabilities to Capital Regulus|RGLS - Company Debts|Debt to Net Assets Ratio Regulus Therapeutics, Inc.|RGLS - Company Long-Term Debts|Company Short-Term Debts Regulus Therapeutics|Critical Liquidity Ratio regulusrx.com
- financial results and valuation multiples details:
RGLS - Net Profit|Expected Net Profit Regulus Therapeutics|RGLS - Price to Earnings Ratio|Forward P/E Multiple Regulus Therapeutics, Inc.|RGLS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Regulus Therapeutics, Inc.|RGLS - Operating profit EBITDA|Net earnings per share for the last four quarters Regulus Therapeutics|RGLS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months regulusrx.com|RGLS - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Regulus Therapeutics
Initial company analysis:regulusrx.com RGLS
Regulus Therapeutics (RGLS) is developing a complex supply infrastructure for the production of RNA drugs. This process directly impacts the trailing 12-month year-over-year EPS dynamics, which measure the rolling growth of earnings per share. This metric reveals the business's ability to offset the cost of capital during periods of liquidity shortages. The stability of the chart confirms the effectiveness of raw material stream diversification and the high margins of the tests. The indicator's current trajectory determines the resilience of the asset's market value.
Competitor analysis for Regulus Therapeutics
TEM - Net earnings per share (EPS TTM)|Qiagen (QGEN) - Earnings per share for the last twelve months|IONS - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RGEN|RNA: Earnings per share for the trailing year|Net earnings per share for the last 12 months CRSP (CRISPR Therapeutics AG)|Earnings per share for the last four quarters WGS|Net earnings per share (EPS TTM) RARE (Ultragenyx)|Earnings per share for the trailing year BEAM|Sarepta Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Twist Bioscience Corp|10x Genomics, Inc. (TXG) - Earnings per share for the last twelve months|intelliatx.com - Earnings per share for the trailing year|STOK (Stoke Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) BioLife Solutions Inc|Earnings per share for the last twelve months Wave Life Sciences Corp (WVE)|MAZE: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) SION (Sionna Therapeutics Inc)|primemedicine.com (PRME) - Net earnings per one share for the last twelve months|TSHA: Net earnings per share for the last 12 months|QURE - Net earnings per share (EPS TTM)|MGTX (MeiraGTx PLC) - Net earnings per share for the last 12 months|RGNX: Earnings per share for the last four quarters|SLDB (Solid Biosciences Inc.) - Net earnings per share (EPS TTM)|ocugen.com (OCGN) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) PACB|Net earnings per share for the last 12 months Benitec Biopharma Inc BNTC|Earnings per share for the last twelve months Design Pharma DSGN|Net earnings per share for the last four quarters Rocket Corp (RCKT)|FDMT - Earnings per share for the last twelve months|Earnings per share for the trailing year LXEO (Lexeo Therapeutics)|KRRO: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Editas Medicine Inc EDIT|Earnings per share for the last twelve months Silence Therapeutics Inc.|Earnings per share for the last twelve months PRQR|Earnings per share for the last twelve months Codexis, Inc. (CDXS)|Net earnings per share for the last four quarters sangamo.com|Net earnings per share (EPS TTM) NAUT (Nautilus Bio)|MGX: Earnings per share for the last 12 months|DTIL - Earnings per share for the last twelve months|GBIO (Generation Bio Co.) - Earnings per share for the last 12 months|BOLD: Net earnings per share (EPS TTM)|Exicure (XCUR) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Imunon Inc|PHIO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) MBIO|RNAZ - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) BNGO (Bionano Genomics)|Net earnings per share for the trailing year adnas.com|BLUE: Net earnings per share for the last 12 months|IPA - Net earnings per share (EPS TTM)|Omega (OMGA) - Earnings per share for the last twelve months|OMIC (Singular Genomics Corp) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months SYRS|Net earnings per share (EPS TTM) telesisbio.com|Earnings per share for the last twelve months TRACON Pharmaceuticals, Inc. (TCON)|Net earnings per share for the last four quarters Unity Biotechnology Inc.
